Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. (Q43803622)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lisa Bodei

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stefano Severi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Maddalena Sansovini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Annarita Ianniello

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stefania Nicoletti

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Laura Gilardi

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

27 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

number of pages

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

881-888

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23443937%20AND%20SRC:MED&resulttype=core&format=json

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

A new dimension of FDG-PET interpretation: assessment of tumor biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Novel Anticancer Agents in Clinical Trials for Well-Differentiated Neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2369-Z

The ENETS guidelines: the new TNM classification system

21 January 2018

1 reference

12 December 2020

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

[What's new? The 2010 WHO classification for tumours of the pancreas]

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020